2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Neoplasms
3214
Carcinoma, Non-Small-Cell Lung
2727
Breast Neoplasms
2550
Colorectal Neoplasms
1461
Prostatic Neoplasms
1307
Neoplasm Metastasis
1300
Multiple Myeloma
1112
Melanoma
1103
Ovarian Neoplasms
1006
Lung Neoplasms
944
Recurrence
924
Leukemia, Myeloid, Acute
879
Pancreatic Neoplasms
832
Lymphoma, Non-Hodgkin
767
Lymphoma
713
Stomach Neoplasms
692
Carcinoma, Renal Cell
660
Carcinoma, Hepatocellular
647
Leukemia, Lymphocytic, Chronic, B-Cell
560
Squamous Cell Carcinoma of Head and Neck
550
Lymphoma, Follicular
515
Head and Neck Neoplasms
490
Glioblastoma
472
Small Cell Lung Carcinoma
447
Lymphoma, Large B-Cell, Diffuse
440
Triple Negative Breast Neoplasms
435
Advanced Solid Tumors
432
Leukemia
426
Uterine Cervical Neoplasms
420
Urinary Bladder Neoplasms
405
Interventions
sacituzumab govitecan
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Triple Negative Locally Advanced Non-resectable Breast Cancer
×
Clear all
NCT06827613
2025-09-24
START-002
Marengo Therapeutics, Inc.
Phase 1/2
Recruiting
50 enrolled